Unknown

Dataset Information

0

The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress.


ABSTRACT:

Background

Evidence suggests that mammalian target of rapamycin activation mediates ketamine's rapid but transient antidepressant effects and that glycogen synthase kinase-3? inhibits this pathway. However, ketamine has associated psychotomimetic effects and a high risk of abuse. The mood stabilizer lithium is a glycogen synthase kinase-3 inhibitor with strong antisuicidal properties. Here, we used a mouse stress model to investigate whether adjunct lithium treatment would potentiate ketamine's antidepressant-like effects.

Methods

Mice received chronic restraint stress and long-term pre- or postketamine lithium treatment in drinking water. The effects of lithium on ketamine-induced antidepressant-like effects, activation of the mammalian target of rapamycin/brain-derived neurotrophic factor signaling pathways, oxidative stress, and dendritic spine density in the brain of mice were investigated.

Results

Subtherapeutic (600 mg/L) lithium-pretreated mice exhibited an antidepressant-like response to an ineffective ketamine (2.5 mg/kg, intraperitoneally) challenge in the forced swim test. Both the antidepressant-like effects and restoration of dendritic spine density in the medial prefrontal cortex of stressed mice induced by a single ketamine (50 mg/kg) injection were sustained by postketamine treatment with 1200 mg/L of lithium for at least 2 weeks. These benefits of lithium treatments were associated with activation of the mammalian target of rapamycin/brain-derived neurotrophic factor signaling pathways in the prefrontal cortex. Acute ketamine (50 mg/kg) injection also significantly increased lipid peroxidation, catalase activity, and oxidized glutathione levels in stressed mice. Notably, these oxidative stress markers were completely abolished by pretreatment with 1200 mg/L of lithium.

Conclusions

Our results suggest a novel therapeutic strategy and justify the use of lithium in patients who benefit from ketamine.

SUBMITTER: Chiu CT 

PROVIDER: S-EPMC4438544 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress.

Chiu Chi-Tso CT   Scheuing Lisa L   Liu Guangping G   Liao Hsiao-Mei HM   Linares Gabriel R GR   Lin Dora D   Chuang De-Maw DM  

The international journal of neuropsychopharmacology 20141228 6


<h4>Background</h4>Evidence suggests that mammalian target of rapamycin activation mediates ketamine's rapid but transient antidepressant effects and that glycogen synthase kinase-3β inhibits this pathway. However, ketamine has associated psychotomimetic effects and a high risk of abuse. The mood stabilizer lithium is a glycogen synthase kinase-3 inhibitor with strong antisuicidal properties. Here, we used a mouse stress model to investigate whether adjunct lithium treatment would potentiate ket  ...[more]

Similar Datasets

| S-EPMC6464213 | biostudies-literature
| S-EPMC3822818 | biostudies-literature
| S-EPMC5553856 | biostudies-other
| S-EPMC5561310 | biostudies-other
| S-EPMC4525684 | biostudies-literature
| S-EPMC4540653 | biostudies-literature
| S-EPMC3102293 | biostudies-literature
| S-EPMC9160425 | biostudies-literature
| S-EPMC4922311 | biostudies-literature
| S-EPMC8011999 | biostudies-literature